Terminated PHASE3 NCT00162695

Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Conditions Malignant Soft Tissue Rhabdomyosarcoma

Interventions Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide

Updated 4 times since 2017 Last updated: Sep 9, 2005 Started: Jul 31, 1995

Listed as NCT00162695, this PHASE3 trial focuses on Malignant Soft Tissue and Rhabdomyosarcoma and remains terminated or withdrawn. Sponsored by Gustave Roussy, Cancer Campus, Grand Paris, it has been updated 4 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2017 — Jan 2021 [monthly]

Terminated PHASE3

First recorded

Jul 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gustave Roussy, Cancer Campus, Grand Paris

Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Villejuif, France